KRAS and neoplasm: While the MC38 orthotopic tumor model serves as a syngeneic murine model generated from wt-KRAS, MSI-H, and p-53 mutant MC38 cell line, we demonstrated as a proof-of-concept, the combination treatment could be effective in studying the mechanisms of immune modulation in response to CB (36).